ArticleBlood2014
Trends in survival of patients with primary plasma cell leukemia: a population-based analysis.
Article in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.
- The use of novel agents in multiple myeloma patients with hepatic impairment.Future oncology (London, England) · 2015Pooled it
- Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.Blood cancer journal · 2018Trial
- Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.Blood advances · 2026Article
- Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia.American journal of hematology · 2026Article
- Uncommon initial presentation of a gastric mass in a patient with primary plasma cell leukemia: a case report.BMC gastroenterology · 2026Article
- Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients.Blood cancer journal · 2026Article
- Outcomes of pPCL Diagnosed Using the IMWG 2021 Consensus Definition: A Retrospective Multicenter Analysis.Cancers · 2026Article
- Defining High-Risk Disease Biology in Multiple Myeloma: A Narrative Review.Blood and lymphatic cancer : targets and therapy · 2026Review
- Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.Blood advances · 2025Article
- Characteristics and Outcomes of Second Primary Multiple Myeloma in Adult Cancer Survivors: A Population-Based Cohort Study.Cancer medicine · 2025Article
- Outcomes and treatment patterns in primary and secondary plasma cell leukemia: insights from a large US cohort study.Haematologica · 2025Article
- Primary Plasma Cell Leukemia: Recent Advances in Molecular Understanding and Treatment Approaches.International journal of molecular sciences · 2025Review
- Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria.Acta haematologica · 2025Article
- T-Cell Engagers In Multiple Myeloma: A Clinical Review.Blood and lymphatic cancer : targets and therapy · 2025Review
- Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter AnalysisTurkish journal of haematology : official journal of Turkish Society of Haematology · 2024Article
- Current Status on Management of Primary Plasma Cell Leukemia.Current oncology reports · 2024Review
- Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States.Leukemia · 2024Article
- Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report.Frontiers in immunology · 2024Article
- Sequential autologous and allogeneic stem cell transplantation for treatment of primary plasma cell leukemia: A case report.Molecular and clinical oncology · 2023Article
- Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling.Haematologica · 2023Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
Abstract
Primary plasma cell leukemia (pPCL) is a rare malignancy with an aggressive course and poor outcome. There has been significant improvement in the survival of multiple myeloma patients over the past decade as a result of incorporating autologous stem cell transplantation (ASCT) and novel agents into treatment regimens. However, it is unknown whether these therapies have had a similar impact on the survival of patients with pPCL. We conducted an analysis of the Surveillance, Epidemiology, and End Results database to evaluate the trends in survival of 445 patients with pPCL between 1973 and 2009. The widespread availability of ASCT and use of novel agents in the upfront setting of multiple myeloma and pPCL began after 1995 and 2006, respectively. The median overall survival based on periods of diagnosis were 5, 6, 4, and 12 months for those diagnosed during 1973-1995, 1996-2000, 2001-2005, and 2006-2009, respectively (P = .001). Thus, the current study confirms the recent survival improvement in pPCL within a large US population that may be associated with the use of better therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.